Evidence map›Paper›PMID 40486453›Full record

ArticleCureus2025

Urinary Pregnanediol-3-Glucuronide and Pregnancy Outcomes in Frozen Embryo Transfer Cycles: A Pilot Study.

Konstantinos Stavridis, Dimitrios Balafoutas, Stavroula-Lila Kastora, Theodoros Kalampokas, Mara Simopoulou, Ralf Joukhadar, Nikos Vlahos

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Konstantinos StavridisDepartment of Obstetrics and Gynaecology, Aretaieion University Hospital, Athens, GRC.
Dimitrios BalafoutasDepartment of Obstetrics and Gynaecology, Aretaieion University Hospital, Athens, GRC.
Stavroula-Lila KastoraFaculty of Population Health Sciences, EGA (Elizabeth Garrett Anderson) Institute for Women's Health, University College London, London, GBR.
Theodoros KalampokasDepartment of Obstetrics and Gynaecology, Aretaieion University Hospital, Athens, GRC.
Mara SimopoulouDepartment of Obstetrics and Gynaecology, Aretaieion University Hospital, Athens, GRC.
Ralf JoukhadarDepartment of Obstetrics and Gynaecology, University Hospital of Würzburg, Würzburg, DEU.
Nikos VlahosDepartment of Obstetrics and Gynaecology, Aretaieion University Hospital, Athens, GRC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Frozen embryo transfers (FETs) have become more common than fresh transfers over the past decade. Progesterone levels around embryo transfer day are known to impact reproductive outcomes, albeit no clear guidelines exist regarding the optimal route, dosage, or duration of luteal phase support (LPS). A circulating progesterone threshold of about 10 ng/mL is generally accepted, but varying endometrial absorption across administration routes challenges its reliability, suggesting a need for validation through alternative progesterone measurement methods. Pregnanediol-3-glucuronide (PDG), the main urinary metabolite of progesterone, may serve as a non-invasive marker for monitoring support. This study aims to explore the association between PDG levels and pregnancy outcomes in FET cycles. Materials and methods This prospective pilot study was conducted at a private in vitro fertilization (IVF) center in Greece from October 2022 to May 2023. Nineteen patients undergoing FET with autologous or donor oocytes were included. Eligible participants were ≤50 years old, had a triple-layer endometrial thickness ≥6.5 mm, and received vaginal progesterone for LPS. Exclusion criteria included intrauterine anomalies, kidney disease, fresh cycles, or use of alternative endometrial preparation protocols. All patients received oral estradiol (2 mg every eight hours) for 14 days, followed by vaginal progesterone (200 mg every six hours). Spot urine samples were collected approximately 10 minutes post-transfer to assess PDG levels through ELISA (Enzyme-Linked Immunosorbent Assay). The primary outcome was the ongoing pregnancy rate (OPR); secondary outcomes included clinical pregnancy rate (CPR), biochemical pregnancy (BP), miscarriage rate (MR), and live birth rate (LBR). Results The median urinary PDG level was 3.5 pg/mL (interquartile range (IQR): 2.0-5.0); 21% of patients had values above 10 pg/mL, exceeding the assay's upper detection limit. No significant associations were found between urinary PDG levels and any pregnancy outcomes (p > 0.05). A significant correlation was observed only between endometrial thickness and CPR (p < 0.05). Conclusion In this pilot cohort, urinary PDG levels on embryo transfer day showed no significant association with pregnancy outcomes, though the small sample size may limit conclusions. Larger studies, with standardized 24-hour urine collection, are needed to assess PDG's role in optimizing LPS in FET cycles.

Indexed as

fetluteal-phase supportpdgpregnancy outcomesurinary progesterone

Identifiers

PMID40486453
PMCPMC12144660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.